DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ha, Tae Kwang | ko |
dc.contributor.author | Lee, Gyun Min | ko |
dc.date.accessioned | 2019-05-02T00:50:18Z | - |
dc.date.available | 2019-05-02T00:50:18Z | - |
dc.date.created | 2019-04-30 | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | PHARMACEUTICAL BIOPROCESSING, v.3, no.3, pp.249 - 261 | - |
dc.identifier.issn | 2048-9145 | - |
dc.identifier.uri | http://hdl.handle.net/10203/261693 | - |
dc.description.abstract | The biopharmaceutical market is driven by the steady increase in demand for therapeutic proteins produced in mammalian cells. Glutamine is a main nitrogen source and also a main energy source with glucose in mammalian cell cultures for therapeutic protein production. As a result of glutamine metabolism and the natural decomposition of glutamine, ammonia, which is known to negatively affect cell growth, protein production and sialylation of recombinant glycoprotein, is necessarily accumulated in a culture medium. This review highlights the current strategies and achievements in overcoming the negative effect of ammonia through the glutamine substitution by less ammoniagenic substrates, such as glutamate, pyruvate and a-ketoglutarate. | - |
dc.language | English | - |
dc.publisher | OPEN ACCESS JOURNALS | - |
dc.title | Glutamine substitution: the role it can play to enhance therapeutic protein production | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.citation.volume | 3 | - |
dc.citation.issue | 3 | - |
dc.citation.beginningpage | 249 | - |
dc.citation.endingpage | 261 | - |
dc.citation.publicationname | PHARMACEUTICAL BIOPROCESSING | - |
dc.identifier.doi | 10.4155/PBP.15.6 | - |
dc.contributor.localauthor | Lee, Gyun Min | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Review | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.